The changing landscape of adverse drug events associated with chronic hepatitis C virus therapy

被引：4

作者：

Smith, Michael A. ^{[1
]}

Love, Bryan L. ^{[2
]}

Mohammad, Rima A. ^{[3
]}

机构：

[1] Univ Sci, Clin Pharm, Philadelphia Coll Pharm, Dept Pharm Practice & Pharm Adm, Philadelphia, PA USA

[2] South Carolina Coll Pharm, GI Hepatol, WJB Dorn VAMC, Dept Clin Pharm & Outcomes Sci, Columbia, SC USA

[3] Univ Michigan, Coll Pharm, Gen Surg Nutr, Univ Michigan Hlth Syst,Dept Clin Pharm, Ann Arbor, MI 48109 USA

来源：

EXPERT OPINION ON DRUG SAFETY | 2015年 / 14卷 / 11期

关键词：

adverse drug events; hepatitis C virus; ledipasvir; sofosbuvir; COMBINATION THERAPY; GENOTYPE; INFECTION; RIBAVIRIN; GRAZOPREVIR; SOFOSBUVIR; INTERFERON;

D O I：

10.1517/14740338.2015.1088002

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Treatment of chronic hepatitis C virus (HCV) therapy has rapidly changed since the approval of IFN in the 1990s. Early treatment brought about significant and therapy limiting adverse drug events (ADEs) such as anemia. Since the direct-acting antivirals were first approved in 2011 and then advanced in 2013, treatment-related ADEs and therapy discontinuations have rapidly decreased, while sustained virologic response rates have significantly increased. As the market for treating chronic HCV therapy has changed, so too has the ADE profile clinicians may need to manage.

引用

页码：1649 / 1652

页数：4

共 16 条

[11] ABT-450/r-Ombitasvir and Dasabuvir with Ribavirin for Hepatitis C with Cirrhosis [J].

Poordad, Fred ;

Hezode, Christophe ;

Trinh, Roger ;

Kowdley, Kris V. ;

Zeuzem, Stefan ;

Agarwal, Kosh ;

Shiffman, Mitchell L. ;

Wedemeyer, Heiner ;

Berg, Thomas ;

Yoshida, Eric M. ;

Forns, Xavier ;

Lovell, Sandra S. ;

Da Silva-Tillmann, Barbara ;

Collins, Christine A. ;

Campbell, Andrew L. ;

Podsadecki, Thomas ;

Bernstein, Barry .

NEW ENGLAND JOURNAL OF MEDICINE, 2014, 370 (21) :1973-1982

[12] Safety of direct-acting antivirals in the treatment of chronic hepatitis C [J].

Ridruejo, Ezequiel .

EXPERT OPINION ON DRUG SAFETY, 2014, 13 (03) :307-319

[13] Ledipasvir-Sofosbuvir: Interferon-/ Ribavirin-Free Regimen for Chronic Hepatitis C Virus Infection [J].

Smith, Michael A. ;

Chan, Juliana ;

Mohammad, Rima A. .

ANNALS OF PHARMACOTHERAPY, 2015, 49 (03) :343-350

[14] Daclatasvir plus Sofosbuvir for Previously Treated or Untreated Chronic HCV Infection [J].

Sulkowski, Mark S. ;

Gardiner, David F. ;

Rodriguez-Torres, Maribel ;

Reddy, K. Rajender ;

Hassanein, Tarek ;

Jacobson, Ira ;

Lawitz, Eric ;

Lok, Anna S. ;

Hinestrosa, Federico ;

Thuluvath, Paul J. ;

Schwartz, Howard ;

Nelson, David R. ;

Everson, Gregory T. ;

Eley, Timothy ;

Wind-Rotolo, Megan ;

Huang, Shu-Pang ;

Gao, Min ;

Hernandez, Dennis ;

McPhee, Fiona ;

Sherman, Diane ;

Hindes, Robert ;

Symonds, William ;

Pasquinelli, Claudio ;

Grasela, Dennis M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2014, 370 (03) :211-221

[15] Grazoprevir-Elbasvir Combination Therapy for Treatment-Naive Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis C Virus Genotype 1, 4, or 6 Infection A Randomized Trial [J].

Zeuzem, Stefan ;

Ghalib, Reem ;

Reddy, K. Rajender ;

Pockros, Paul J. ;

Ben Ari, Ziv ;

Zhao, Yue ;

Brown, Deborah D. ;

Wan, Shuyan ;

DiNubile, Mark J. ;

Bach-Yen Nguyen ;

Robertson, Michael N. ;

Wahl, Janice ;

Barr, Eliav ;

Butterton, Joan R. .

ANNALS OF INTERNAL MEDICINE, 2015, 163 (01) :1-13

[16] Retreatment of HCV with ABT-450/r-Ombitasvir and Dasabuvir with Ribavirin [J].

Zeuzem, Stefan ;

Jacobson, Ira M. ;

Baykal, Tolga ;

Marinho, Rui T. ;

Poordad, Fred ;

Bourliere, Marc ;

Sulkowski, Mark S. ;

Wedemeyer, Heiner ;

Tam, Edward ;

Desmond, Paul ;

Jensen, Donald M. ;

Di Bisceglie, Adrian M. ;

Varunok, Peter ;

Hassanein, Tarek ;

Xiong, Junyuan ;

Pilot-Matias, Tami ;

DaSilva-Tillmann, Barbara ;

Larsen, Lois ;

Podsadecki, Thomas ;

Bernstein, Barry .

NEW ENGLAND JOURNAL OF MEDICINE, 2014, 370 (17) :1604-1614

← 1 2 →